PetVivo Holdings, Inc. (PETV)
USD 0.63
(4.99%)
USD 0.63
(4.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 2.42 Million USD | 41.74% |
| 2023 | 1.71 Million USD | 18.97% |
| 2022 | 1.44 Million USD | -16.83% |
| 2021 | 1.73 Million USD | 11.13% |
| 2020 | 1.55 Million USD | 1.48% |
| 2019 | 1.53 Million USD | 7.33% |
| 2018 | 1.43 Million USD | 32.86% |
| 2017 | 1.07 Million USD | -27.16% |
| 2016 | 1.47 Million USD | 145.83% |
| 2015 | 601.6 Thousand USD | 25.56% |
| 2014 | 479.14 Thousand USD | 86.83% |
| 2013 | 256.46 Thousand USD | 43.3% |
| 2012 | 178.97 Thousand USD | 127.33% |
| 2011 | 78.72 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.07 Million USD | 13.78% |
| 2024 Q3 | 2.73 Million USD | -11.01% |
| 2024 Q4 | 2.42 Million USD | -11.17% |
| 2024 FY | 2.42 Million USD | 41.74% |
| 2024 Q1 | 2.7 Million USD | 57.59% |
| 2023 Q1 | 1.47 Million USD | 2.11% |
| 2023 Q2 | 1.48 Million USD | 1.11% |
| 2023 Q4 | 1.71 Million USD | -3.94% |
| 2023 FY | 1.71 Million USD | 18.97% |
| 2023 Q3 | 1.78 Million USD | 19.95% |
| 2022 Q4 | 1.44 Million USD | 15.6% |
| 2022 FY | 1.44 Million USD | -16.83% |
| 2022 Q2 | 1.36 Million USD | -17.77% |
| 2022 Q1 | 1.66 Million USD | -4.11% |
| 2022 Q3 | 1.24 Million USD | -8.76% |
| 2021 Q2 | 2.65 Million USD | 23.18% |
| 2021 Q3 | 1.56 Million USD | -41.18% |
| 2021 FY | 1.73 Million USD | 11.13% |
| 2021 Q1 | 2.15 Million USD | 38.22% |
| 2021 Q4 | 1.73 Million USD | 10.97% |
| 2020 Q4 | 1.55 Million USD | 10.72% |
| 2020 Q1 | 1.89 Million USD | 23.26% |
| 2020 Q2 | 1.44 Million USD | -23.56% |
| 2020 Q3 | 1.4 Million USD | -2.73% |
| 2020 FY | 1.55 Million USD | 1.48% |
| 2019 Q4 | 1.53 Million USD | 2.56% |
| 2019 Q3 | 1.49 Million USD | -5.48% |
| 2019 Q2 | 1.58 Million USD | 14.32% |
| 2019 Q1 | 1.38 Million USD | -3.15% |
| 2019 FY | 1.53 Million USD | 7.33% |
| 2018 FY | 1.43 Million USD | 32.86% |
| 2018 Q4 | 1.43 Million USD | -13.62% |
| 2018 Q3 | 1.65 Million USD | 0.57% |
| 2018 Q2 | 1.64 Million USD | 5.63% |
| 2018 Q1 | 1.55 Million USD | 44.79% |
| 2017 FY | 1.07 Million USD | -27.16% |
| 2017 Q1 | 1.59 Million USD | 8.16% |
| 2017 Q2 | 1.8 Million USD | 12.61% |
| 2017 Q3 | 2.01 Million USD | 11.8% |
| 2017 Q4 | 1.07 Million USD | -46.51% |
| 2016 Q1 | 2.75 Million USD | 358.33% |
| 2016 Q3 | 2.99 Million USD | 6.48% |
| 2016 Q2 | 2.81 Million USD | 1.95% |
| 2016 Q4 | 1.47 Million USD | -50.59% |
| 2016 FY | 1.47 Million USD | 145.83% |
| 2015 Q2 | 162.16 Thousand USD | -74.49% |
| 2015 Q1 | 635.69 Thousand USD | 32.67% |
| 2015 FY | 601.6 Thousand USD | 25.56% |
| 2015 Q4 | 601.6 Thousand USD | -72.31% |
| 2015 Q3 | 2.17 Million USD | 1239.86% |
| 2014 FY | 479.14 Thousand USD | 86.83% |
| 2014 Q3 | 1.06 Million USD | -8.52% |
| 2014 Q2 | 1.16 Million USD | 323.64% |
| 2014 Q1 | 274.62 Thousand USD | 7.08% |
| 2014 Q4 | 479.14 Thousand USD | -54.98% |
| 2013 FY | 256.46 Thousand USD | 43.3% |
| 2013 Q1 | 202.64 Thousand USD | 13.23% |
| 2013 Q3 | 253.45 Thousand USD | 8.16% |
| 2013 Q4 | 256.46 Thousand USD | 1.19% |
| 2013 Q2 | 234.33 Thousand USD | 15.64% |
| 2012 FY | 178.97 Thousand USD | 127.33% |
| 2012 Q2 | 112.22 Thousand USD | 0.0% |
| 2012 Q4 | 178.97 Thousand USD | 31.99% |
| 2012 Q3 | 135.59 Thousand USD | 20.82% |
| 2011 Q4 | 78.72 Thousand USD | 0.0% |
| 2011 FY | 78.72 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acutus Medical, Inc. | 54.83 Million USD | 95.57% |
| Biotricity, Inc. | 35.91 Million USD | 93.237% |
| Cell MedX Corp. | 872.57 Thousand USD | -178.405% |
| Dynatronics Corporation | 11.78 Million USD | 79.378% |
| Nemaura Medical Inc. | 26.37 Million USD | 90.79% |
| RetinalGenix Technologies Inc. | 1.4 Million USD | -72.804% |
| Sonendo, Inc. | 49.74 Million USD | 95.116% |
| Telesis Bio, Inc. | 40.87 Million USD | 94.056% |
| Talis Biomedical Corporation | 29.22 Million USD | 91.687% |
| Viveve Medical, Inc. | 10.84 Million USD | 77.604% |